|
1
|
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
|
Lancet
|
2001
|
3.19
|
|
2
|
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
|
Ann Rheum Dis
|
2005
|
2.08
|
|
3
|
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
|
Arthritis Rheum
|
2007
|
1.21
|
|
4
|
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
|
Ann Rheum Dis
|
2005
|
1.05
|
|
5
|
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
|
Ann Rheum Dis
|
2006
|
1.05
|
|
6
|
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
|
Br J Dermatol
|
2008
|
0.89
|
|
7
|
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
|
Br J Dermatol
|
2005
|
0.89
|
|
8
|
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
|
Br J Dermatol
|
2006
|
0.86
|